Recursion Pharmaceuticals Inc - Class A RXRX

NAS: RXRX | ISIN: DE0007201980   2/04/2026
3,110 USD (+1,63%)
(+1,63%)   2/04/2026

29 januari 2026 · AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift · Persbericht

30 juni 2025 · AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway · Persbericht

16 april 2025 · HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data · Persbericht

1 februari 2023 · Recursion to Participate in Upcoming Investor Conference · Persbericht

26 januari 2023 · Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day · Persbericht

20 december 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

8 november 2022 · Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results · Persbericht

2 november 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

25 oktober 2022 · Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB · Persbericht

13 september 2022 · Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 · Persbericht

1 september 2022 · Recursion to Participate in Upcoming Investor Conferences · Persbericht

18 augustus 2022 · Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum · Persbericht

9 augustus 2022 · Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results · Persbericht

2 augustus 2022 · Recursion to Participate in Upcoming Investor Conference · Persbericht

21 juli 2022 · Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis · Persbericht

Mijn selecties